EGFR and head and neck squamous cell carcinoma: On the other hand, due to high EGFR and VEGFR expressions on HNSCC patients with chemotherapy resistance and poor prognosis, there are multiple combined treatment trials with EGF/EGFR or VEGF/VEGFR axis inhibitor and chemotherapy reported, including cetuximab and cisplatin (107); cetuximab and platinum/5-FU (108); sorafenib and ciplatin/5-FU (111); bevacizumab and cisplatin/IMRT (113); bevacizumab and docetaxel/RT (114).